Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sanofi-Aventis Taps Avila Technology
by Lisa M. Jarvis
January 10, 2011
| A version of this story appeared in
Volume 89, Issue 2
Sanofi-Aventis and Avila Therapeutics will work jointly to discover cancer treatments through Avila’s covalent drug technology, which enables compounds to form permanent bonds with their target proteins. Under the deal, the companies will develop covalent drugs targeting six signaling proteins active in tumor cells. Avila scores $40 million up front and research support. It could earn up to $154 million per compound in milestone payments. The Waltham, Mass.-based biotech firm also gets to keep the rights to one of the molecules at the end of the three-year pact.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter